John L. Marshall, MD; Marwan G. Fakih, MD; and Joleen M. Hubbard, MD, highlight novel strategies in the metastatic colorectal cancer pipeline that look exciting and consider their integration into future clinical practice.
John L. Marshall, MD, MedStar Georgetown University Hospital
Advertisement
Articles by John L. Marshall, MD, MedStar Georgetown University Hospital
The rationale for continuing to study the combination of immunotherapies with novel tyrosine kinase inhibitors in metastatic colorectal cancer.
Implications for using the combination of pembrolizumab and lenvatinib to treat patients with metastatic colorectal cancer based on updated data from the LEAP-005 study.
Considerations for treating patients with metastatic colorectal cancer with the combination of nivolumab and regorafenib based on preliminary data.
Drs. John L. Marshall, Marwan G. Fakih, and Joleen M. Hubbard, describe the current role of chemotherapy for frontline metastatic colorectal cancer based on novel treatment advances.
Considerations for frontline immunotherapy for patients with microsatellite instability high metastatic colorectal cancer based on data from the KEYNOTE-177 and CheckMate 142 studies.
Mayo Clinic’s Joleen M. Hubbard, MD, interprets data recently presented on the use of EGFR inhibitors as frontline therapy for appropriate patients with metastatic colorectal cancer.
Tumor characteristics, patient factors, and supporting data that affect frontline treatment decisions for patients with microsatellite stable (MSS) metastatic colorectal cancer.
Metastatic colorectal cancer (CRC) experts discuss tumor sidedness and their current use of next-generation sequencing panels to assess patients and guide treatment decisions.
Reactions to the increase in prevalence of metastatic colorectal cancer (CRC) among a younger patient population despite treatment advances.
Future of NTRK Fusions
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Challenges for TRK Fusion–Targeting Agents
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Acquired Resistance in TRK Fusion-Positive Cancers
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Approaching Treatment for TRK Fusion–Positive Cancers
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
TRK Inhibitor in GI Cancers: Adverse Effect Profile
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Efficacy of TRK Inhibitors
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Early Development of TRK Inhibitors
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Advice for Interpreting NGS Reports
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Driver Mutations in NTRK Fusion-Positive Cancers
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Genomic Testing for NTRK Fusions in Lung and GI Cancers
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Approaching Genomic Testing for NTRK Fusions
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Using Molecular Testing in GI Cancers
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Evolution of NGS Testing in Lung Cancers
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Variants of NTRK Fusions in Solid Tumors
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Role of NTRK Inhibitors
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Advertisement
Latest Updated Articles
Metastatic CRC: Pembrolizumab Plus LenvatinibPublished: August 17th 2021 | Updated:
Treating Metastatic CRC With TKI/I-O CombinationsPublished: August 24th 2021 | Updated:
MSS Metastatic CRC: First-Line Treatment SelectionPublished: August 3rd 2021 | Updated:
Novel Approaches Under Study for Metastatic CRCPublished: August 24th 2021 | Updated:
Metastatic CRC: Nivolumab Plus RegorafenibPublished: August 17th 2021 | Updated:
Metastatic CRC: Frontline Therapy With EGFR InhibitorsPublished: August 3rd 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5